Predict your next investment

INTERNET | Internet Software & Services / Healthcare

See what CB Insights has to offer


Incubator/Accelerator | Alive

About Miamed

Miamed is the developer of Amboss, a medical knowledge platform for medical students and practitioners.

Miamed Headquarter Location

Sachsenring 73

Cologne, 50677,



Latest Miamed News

Amicus Takes Aim at Rare Brain Disorder with MiaMed Acquisition

Jul 7, 2016

XconomyNew York —  Rare disease drug developer Amicus Therapeutics has added a new prospect to its pipeline with the acquisition of a biologic program that the company hopes will eventually treat a genetic disorder whose seizures and neurological impairments have no approved treatment or cure. That preclinical program comes from MiaMed, a company that Amicus (NASDAQ: [[FOLD]]) said it acquired on Wednesday. Amicus paid about $6.5 million—$1.8 million in cash and $4.7 million in Amicus stock, according to a press release announcing the deal. The Cranbury, NJ-based company will pay MiaMed shareholders up to $18 million more if the program achieves clinical and regulatory milestones, and an additional $65 million if Amicus successfully brings a new treatment to market. Those milestones could be paid in some combination of cash or Amicus stock, the company said in a regulatory filing . MiaMed focused on replacing a missing protein involved in normal brain development. People who don’t make enough of this protein, called cyclin-dependent kinase-like 5 (CDKL5), start having seizures in infancy, according to the National Organization for Rare Disorders . Later, these patients may go on to have trouble walking, talking, or feeding themselves, and many are confined to wheelchairs. Amicus says there are more than 1,200 documented cases of CDKL5 deficiency worldwide, a number that is increasing as genetic testing for the disorder becomes more common. The CDKL5 program joins an Amicus pipeline that has several compounds in later stages of development. In May, the company received European approval for migalastat (Galafold), a treatment for Fabry disease . The rare disorder renders the body unable to clear out a certain type of fat, which can then damage the kidneys or lead to heart attacks. Amicus’ drug pipeline also includes a compound in mid-stage clinical trials as a potential treatment for the rare skin disorder epidermolysis bullosa , and another being studied in Pompe disease, a disorder in which an enzyme deficiency impairs muscular function. In a prepared statement, Amicus CEO John Crowley said that while the company is focused on launching the Fabry disease drug and advancing its other drug candidates, the CDKL5 program fits the company’s strategy of expanding its biologics pipeline. Image courtesy of Flicker user DJ under a Creative Commons license.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Miamed

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Miamed is included in 1 Expert Collection, including Digital Health.


Digital Health

11,674 items

Companies using/incorporating digital tech into health, wellness, and life science offerings. Includes cos operating within the hc, consumer health, and life science industries + tech vendors catering to them. Excludes cos exclusively focused on fitness/sports & performance

Miamed Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Miamed Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.